IGC Pharma, Inc. revenue by segment IGC

Annual Quarterly

IGC Pharma, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Mar 31, 2025 was White Labeling Services at $1.2 million, 91% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019	FY 2018 Mar 31, 2018	FY 2017 Mar 31, 2017	FY 2016 Mar 31, 2016
Revenue	1	1	1	1	0	1	4	5	2	1	6
White Labeling Services	1 share 91.4%	1 +21.5% share 91.1%	1 +149.5% share 70.9%	0 +788.4% share 41.9%	0 share 10.8%	—	—	—	—	—	—
Other Revenue	—	—	0 share 12.2%	—	—	—	—	—	—	—	—
Wellness And Lifestyle	0 share 10.8%	0 -50.4% share 8.9%	0 -45.2% share 17.0%	0 +31.6% share 45.7%	0 share 79.6%	—	—	—	—	—	—
Construction	—	—	—	0 +406.7% share 8.3%	0 share 3.8%	—	—	—	—	—	—
Rental Income	—	—	—	0 +60.9% share 4.1%	0 share 5.8%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: IGC (NYSE)
Fiscal year ends: December 31
Incorporated in: MD
Headquarters: Potomac, MD
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1326205
Former names: India Globalization Capital, Inc. (until Mar 21, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.